Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979570 · ClinicalTrials.gov registry record · NA
Personalized Performance Optimization Platform
A NA study of Neurocognitive Function and Sensory Science, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 2
- Study locations
NCT06979570 is a NA study of Neurocognitive Function and Sensory Science that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 303-participant average among 3 other Neurocognitive Function trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06979570, a NA study of Neurocognitive Function and Sensory Science, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 2
- Study locations
Study Summary
Crews of future long-duration exploration missions will have to cope with a wide range of stressors that present significant challenges for maintaining optimal performance. Crews will have to operate under conditions of high workload, reduced sleep and circadian dysregulation, limited sensory stimulation, confinement and extended separation from family and friends, and communication delays isolating them from real-time interaction with ground support, which may be particularly critical in the event of emergencies. These factors present significant risks to optimal cognitive/behavioral functioning and performance, across individuals and teams, and such challenges will only increase in criticality as human exploration moves beyond Earth's orbit to targets such as the Moon and Mars. To help mitigate these risks, Massachusetts General Hospital, along with collaborators at the Massachusetts Institute of Technology, will investigate a novel, personalized and scalable, closed-loop platform technology for on-board behavioral health management-one which adapts the local working environment to optimize performance based on biosensor feedback.
Conditions Studied
Interventions
- DEVICE AttentivU
Study Locations (2)
Massachusetts
- MIT Media Lab - Cambridge
- Massachusetts General Hospital - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-02-22 |
| Est. Completion | 2025-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06979570
The ClinicalTrials.gov registry entry for NCT06979570 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 303-participant average among 3 other Neurocognitive Function trials with a reported enrollment target (74% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Neurocognitive Function appearing as the primary indexed condition, and to 1 intervention - of which AttentivU is the first listed.
NCT06979570 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06979570 about?
NCT06979570 is a clinical study titled "Personalized Performance Optimization Platform". Crews of future long-duration exploration missions will have to cope with a wide range of stressors that present significant challenges for maintaining optimal performance. Crews will have to operate under conditions of high workload, reduced sleep and circadian dysregulation, limited sensory stimul...
What is the current status of trial NCT06979570?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2021-02-22. Estimated completion is 2025-12-30.
What conditions does trial NCT06979570 study?
This clinical trial studies the following conditions: Neurocognitive Function, Sensory Science, Performance Assessment, Countermeasure Evaluation, Psychological Factors.
What interventions are being tested in trial NCT06979570?
The interventions under investigation include: AttentivU (DEVICE).
Who is sponsoring clinical trial NCT06979570?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979570 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurocognitive Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
-
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)
RECRUITING · Phase 2
-
UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.